With inflation expectations in the US edging down and wage growth coming in softer than many anticipated, interest rate expectations are shifting again. That puts smaller, financially healthier penny stocks in an interesting spot as investors reassess where to find potential growth and resilience. This article looks at three stocks from the Financially Fit Penny Stocks screener that combine low share prices with balance sheet strength.
The three stocks covered below are just a starting sample, and the full Financially Fit Penny Stocks screen surfaced 320 more companies with equally compelling narratives that are not covered in this article. If you want to move quickly from ideas to a focused watchlist, head straight into the Financially Fit Penny Stocks screener to identify, filter and analyze the setups that best match your criteria.
Ardelyx (ARDX)
Ardelyx focuses on gastrointestinal and kidney disorders, with two commercial drugs, IBSRELA for irritable bowel syndrome with constipation and XPHOZAH for phosphate control in adults with chronic kidney disease on dialysis. The company has a market cap of about US$1.2b, putting it in the mid sized biotech bracket for penny stock investors who are more focused on share price than overall size.
Ardelyx is on many investors’ radar because its approved drugs are already generating record quarterly product revenue in the US kidney and IBS markets, yet the stock still trades at what some models view as a deep discount to estimated fair value. At the same time, you need to weigh concentration in a small product set, payer disputes around Medicare coverage for XPHOZAH and a funding structure that leans on higher cost borrowing. If you want exposure to a commercial stage biotech with clear growth ambitions and real but visible risks, Ardelyx is a story worth looking at more closely.
Ardelyx sits at the crossroads of real product traction and what some models flag as a steep valuation gap, yet the crux of the story sits in the 4 key rewards and 1 important warning sign
Build your own Ardelyx style penny stock shortlist
Ardelyx and the other two stocks in this article all surfaced from a single screener, but the real edge comes when you create your own filters. Use our flexible Screener to mix metrics like valuation, balance sheet strength and risks into a focused watchlist, or jump straight into our curated Investing Ideas for ready made starting points.
Taboola.com (TBLA)
Taboola.com runs an AI powered recommendation platform that sits on publisher sites, devices and apps to serve ads and content across the open web. The company generates essentially all of its revenue from advertising, with about US$2.0b in ad sales spread across markets such as the United States, Israel, Germany, the United Kingdom and the rest of the world. At a market cap of roughly US$1.1b, Taboola.com sits in small cap territory for investors looking at penny stock share prices with a global ad tech footprint.
Taboola.com is worth a closer look if you want exposure to AI driven ad tech that is tied to the open web rather than the big walled gardens. The stock screens as attractively valued on several metrics, while Q2 2026 results and full year revenue guidance around US$1.9b anchor that story in hard numbers. At the same time, analysts expect earnings to soften and highlight funding risk from reliance on external borrowing. The key question is whether new products like Realize and DeeperDive, along with expanding handset partnerships, can offset slower core growth and one off earnings noise over the next few years.
Taboola.com sits where AI, open web traffic and ad dollars intersect, yet many investors still treat it like a plain ad tech stock. The real story sits inside the 3 key rewards and 2 important warning signs (1 is major!)
Hyliion Holdings (HYLN)
Hyliion Holdings develops the KARNO Power Module, a fuel flexible generator for on site power that can run on natural gas, diesel, waste gases or zero carbon fuels like hydrogen and ammonia. The company currently reports about US$6 million in revenue from Auto Parts & Accessories in the United States and has a market cap of roughly US$704 million.
Hyliion Holdings may appeal to investors who want exposure to the push for reliable power for data centers and defense projects without owning a traditional utility. The $41.7 million Office of Naval Research contract and successful multi module KARNO tests indicate operational progress. At the same time, revenue is still small, losses are significant and the company relies on higher risk external funding with a short cash runway. The stock already trades above one fair value estimate, so investors are paying a premium for the company’s ability to advance commercialization, strengthen its supply chain and convert contracts, all of which remain in relatively early stages.
Hyliion Holdings sits at the intersection of early stage power technology and high expectations, but the real tension lies between the current cash burn and what happens if contracts ramp faster than funding improves. The full picture sits in the Hyliion Holdings financial health report
Seeking Fresh Alternatives Beyond Penny Stocks
Markets move fast and the next breakout ideas often sit quietly under the radar for now. Scan these fresh lists before momentum is caught by the crowd and act now.
- Spot cash generative leaders before the crowd by running the 51 high quality undervalued stocks while prices and expectations still look out of sync.
- Follow real revenue stories in AI by checking the 69 profitable AI stocks that aren't just burning cash while many investors still chase companies that are only burning cash.
- Lock in potential income streams early with the 8 dividend fortresses while yields and balance sheets still line up in your favor.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com